Literature DB >> 28325597

Relationships between acrylamide and glycidamide hemoglobin adduct levels and allergy-related outcomes in general US population, NHANES 2005-2006.

Jing Guo1, Dongdong Yu1, Na Lv1, Rongpan Bai1, Chunjing Xu2, Guangdi Chen3, Weiming Cao4.   

Abstract

BACKGROUND: Acrylamide-induced immunotoxicity and allergic dermatitis have been reported in animal experiments and clinical reports, respectively. However, epidemiological evidence from the general population is limited.
OBJECTIVES: The purpose of the present study was to estimate the associations between acrylamide exposure and allergy-related outcomes in the general US population.
METHODS: A total of 6982 subjects were selected from the National Health and Nutrition Examination Survey 2005-2006 (NHANES). Internal exposure was measured by the hemoglobin adducts of acrylamide (HbAA) and its metabolite glycidamide (HbGA). Allergy-related outcomes including asthma, hay fever, allergy, itchy rash, sneeze, wheeze and eczema were obtained by self-administered questionnaires. Allergic sensitization was assessed by the total immunoglobulin E (IgE) levels. The associations of HbAA and HbGA quartiles with allergy-related outcomes were calculated using logistic regression models with multivariable adjustments. Analyses were additionally stratified according to age, gender and serum cotinine levels.
RESULTS: When setting quartile 1 of HbAA as reference, the odds ratios (ORs) [95% confidence intervals (CIs)] of quartile 2 to 4 for eczema were 1.18 (0.79-1.76), 1.14 (0.73-1.78) and 1.58 (1.14-2.18), respectively (ptrend = 0.002). Individuals at the highest quartile of HbGA had significantly elevated likelihoods of itchy rash (OR = 1.37, 95% CI = 1.02-1.83, ptrend = 0.032) and eczema (OR = 1.45, 95% CI = 1.06-1.97, ptrend = 0.044). The stratification analyses indicated various results in different subgroups.
CONCLUSIONS: This study indicated significant associations between HbAA and HbGA levels and the likelihoods of allergy-related outcomes in the general US population, depending on age, gender and smoke exposure status. These findings suggested potential public health concerns for the widespread exposure to acrylamide.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acrylamide; Allergy; Glycidamide; Hemoglobin adducts; NHANES

Mesh:

Substances:

Year:  2017        PMID: 28325597     DOI: 10.1016/j.envpol.2017.03.016

Source DB:  PubMed          Journal:  Environ Pollut        ISSN: 0269-7491            Impact factor:   8.071


  5 in total

1.  An eco-friendly solvent-free reaction based on peptide probes: design an extraction-free method for analysis of acrylamide under microliter volume.

Authors:  Yi-Shan Li; Jau-Ling Suen; Wei-Lung Tseng; Chi-Yu Lu
Journal:  Anal Bioanal Chem       Date:  2021-10-11       Impact factor: 4.478

2.  Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China.

Authors:  Xiangqing Hou; Wenting Luo; Hui Gan; Tianhao Chen; Baoqing Sun
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

3.  Allergy-related outcomes and sleep-related disorders in adults: a cross-sectional study based on NHANES 2005-2006.

Authors:  Yang Xi; Yu-Qin Deng; Shi-Ming Chen; Yong-Gang Kong; Yu Xu; Fen Li; Wo-Er Jiao; Gan Lu; Ze-Zhang Tao
Journal:  Allergy Asthma Clin Immunol       Date:  2022-03-22       Impact factor: 3.406

4.  Level-specific associations of urinary antimony with cognitive function in US older adults from the National Health and Nutrition Examination Survey 2011-2014.

Authors:  Xiangdong Wang; Rui Wang; Zeyao Zhang; Chao Luo; Zixuan Zhao; Junpu Ruan; Rongrong Huang; Hongbing Zhang; Qiyun Wu; Shali Yu; Juan Tang; Xinyuan Zhao
Journal:  BMC Geriatr       Date:  2022-08-12       Impact factor: 4.070

5.  Relationships between urinary metals concentrations and cognitive performance among U.S. older people in NHANES 2011-2014.

Authors:  Xiangdong Wang; Pei Xiao; Rui Wang; Chao Luo; Zeyao Zhang; Shali Yu; Qiyun Wu; Ye Li; Yali Zhang; Hongbing Zhang; Xinyuan Zhao
Journal:  Front Public Health       Date:  2022-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.